{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:15:21Z","timestamp":1780478121975,"version":"3.54.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl. Int."],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) has significantly impacted lung transplant recipients (LTR), who remain vulnerable to severe COVID-19 despite vaccination, prompting the use of monoclonal antibodies (mAbs) as a treatment option. This systematic review summarizes the clinical efficacy of mAbs against COVID-19 in adult LTR and provides a perspective on the role of mAbs for infectious diseases in the future. A systematic search of PubMed\/MEDLINE, Embase and Cochrane was conducted for studies reporting clinical outcomes of adult LTR or solid organ transplant recipients (SOTR) including LTR with drug-specific outcomes. Twelve studies were included. Pre-exposure prophylaxis with mAbs reduced COVID-19 breakthrough infection in LTR. Early treatment of COVID-19 with mAbs correlated with a reduced incidence of severe COVID-19 outcomes, although statistical significance varied among studies. Overall, observational studies have demonstrated a potential benefit of mAbs in the treatment of COVID-19 in LTR, both in prophylaxis and early treatment, as well as the importance of early administration. Moreover, mAb therapy appeared safe and could be a viable option against other pathogens, a route that warrants further investigation.<\/jats:p><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=382133<\/jats:ext-link>, identifier CRD42022382133.<\/jats:p><\/jats:sec>","DOI":"10.3389\/ti.2025.13800","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:07:22Z","timestamp":1739207242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future"],"prefix":"10.3389","volume":"38","author":[{"given":"David A.","family":"Van Eijndhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"220098","DOI":"10.1183\/16000617.0098-2022","article-title":"Prognostic Factors for Mortality, Intensive Care Unit and Hospital Admission Due to SARS-CoV-2: A Systematic Review and Meta-Analysis of Cohort Studies in Europe","volume":"31","author":"Vardavas","year":"2022","journal-title":"Eur Respir Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"n2244","DOI":"10.1136\/bmj.n2244","article-title":"Risk Prediction of COVID-19 Related Death and Hospital Admission in Adults After COVID-19 Vaccination: National Prospective Cohort Study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e4090","DOI":"10.1093\/cid\/ciaa1097","article-title":"Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study","volume":"73","author":"Kates","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1097\/TP.0000000000003670","article-title":"Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-Matched Analysis of a Large Research Network","volume":"105","author":"Hadi","year":"2021","journal-title":"Transplantation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/TP.0000000000004059","article-title":"Real-World Effectiveness of the Pfizer- BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients","volume":"106","author":"Callaghan","year":"2022","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1097\/TP.0000000000003873","article-title":"COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?","volume":"105","author":"Coll","year":"2021","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1111\/ajt.16692","article-title":"COVID-19 in Hospitalized Lung and Non-Lung Solid Organ Transplant Recipients: A Comparative Analysis From a Multicenter Study","volume":"21","author":"Heldman","year":"2021","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e28736","DOI":"10.1002\/jmv.28736","article-title":"SARS\u2010CoV\u20102 Vaccine Antibody Response and Breakthrough Infections in Transplant Recipients","volume":"95","author":"Vanlerberghe","year":"2023","journal-title":"J Med Virol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2420","DOI":"10.1002\/rmv.2420","article-title":"Efficacy and Safety of Tixagevimab\u2010cilgavimab as Pre\u2010Exposure Prophylaxis for COVID\u201019: A Systematic Review and Meta\u2010Analysis","volume":"33","author":"Soeroto","year":"2023","journal-title":"Rev Med Virol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2200502","DOI":"10.1183\/13993003.00502-2022","article-title":"Efficacy of Three COVID-19 Vaccine Doses in Lung Transplant Recipients: A Multicentre Cohort Study","volume":"61","author":"Dauriat","year":"2023","journal-title":"Eur Respir J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e226822","DOI":"10.1001\/jamanetworkopen.2022.6822","article-title":"Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis","volume":"5","author":"Manothummetha","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV Antibody Combination and Outcomes in Outpatients With COVID-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1093\/cid\/ciab912","article-title":"A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load","volume":"75","author":"Dougan","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial","volume":"327","author":"O\u2019Brien","year":"2022","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"New Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/ajt.17098","article-title":"Real-World Experience With Available, Outpatient COVID-19 Therapies in Solid Organ Transplant Recipients during the Omicron Surge","volume":"22","author":"Radcliffe","year":"2022","journal-title":"Am J Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e239694","DOI":"10.1001\/jamanetworkopen.2023.9694","article-title":"Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes","volume":"6","author":"Ambrose","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An Infectious SARS-CoV-2 B.1.1.529 Omicron Virus Escapes Neutralization by Therapeutic Monoclonal Antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jinf.2022.06.027","article-title":"Monoclonal Antibody Therapy Improves Severity and Mortality of COVID-19 in Organ Transplant Recipients: A Meta-Analysis","volume":"85","author":"Yang","year":"2022","journal-title":"J Infect"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1111\/ajt.16192","article-title":"Use of Tocilizumab in Kidney Transplant Recipients with COVID-19","volume":"20","author":"P\u00e9rez-S\u00e1ez","year":"2020","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1002\/iid3.587","article-title":"Early Use of Tocilizumab in Solid Organ Transplant Recipients with COVID\u201019: A Retrospective Cohort Study in Saudi Arabia","volume":"10","author":"Yamani","year":"2022","journal-title":"Immun Inflamm Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a Web and Mobile App for Systematic Reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B26","unstructured":"The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses\n            WellsGA\n            SheaB\n            O\u2019ConnellD"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab Pre-Exposure Prophylaxis Is Associated With Lower Breakthrough Infection Risk in Vaccinated Solid Organ Transplant Recipients During the Omicron Wave","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1654.e1","DOI":"10.1016\/j.cmi.2022.07.015","article-title":"Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab (Evusheld) for COVID-19 Among 1112 Severely Immunocompromised Patients","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B29","doi-asserted-by":"publisher","first-page":"E172","DOI":"10.1093\/cid\/ciac571","article-title":"Clinical Characteristics and Outcomes of Immunocompromised Patients with Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study","volume":"76","author":"Malahe","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e14913","DOI":"10.1111\/ctr.14913","article-title":"Patient-Reported Outcomes after Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis Among Solid Organ Transplant Recipients: Safety, Effectiveness, and Perceptions of Risk","volume":"37","author":"Alejo","year":"2023","journal-title":"Clin Transpl"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1097\/TP.0000000000004418","article-title":"COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-Cilgavimab Prophylaxis And\/or Bebtelovimab Treatment in a Nurse-Driven Monoclonal Antibody Program during the Omicron Surge","volume":"107","author":"Cochran","year":"2023","journal-title":"Transplantation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/cid\/ciac324","article-title":"Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients during the Omicron Wave","volume":"75","author":"Solera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/bcp.15644","article-title":"Experience With Sotrovimab Treatment of SARS-CoV-2-Infected Patients in Denmark","volume":"89","author":"Rasmussen","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e13901","DOI":"10.1111\/tid.13901","article-title":"Outcomes of Bebtelovimab and Sotrovimab Treatment of Solid Organ Transplant Recipients with Mild-To-Moderate Coronavirus Disease 2019 During the Omicron Epoch","volume":"24","author":"Yetmar","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1111\/ajt.17140","article-title":"COVID-19 Therapeutics and Outcomes Among Solid Organ Transplant Recipients during the Omicron BA.1 Era","volume":"22","author":"Hedvat","year":"2022","journal-title":"Am J Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"E424","DOI":"10.1097\/TP.0000000000004217","article-title":"Short-term Outcomes in a Nurse Coordinator-Led and Nurse Practitioner-Led Sotrovimab Initiative for Solid Organ Transplant Recipients During the Omicron Surge","volume":"106","author":"Cochran","year":"2022","journal-title":"Transplantation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"ofab255","DOI":"10.1093\/ofid\/ofab255","article-title":"Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients","volume":"8","author":"Yetmar","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e13759","DOI":"10.1111\/tid.13759","article-title":"Monoclonal Antibody Treatment for COVID-19 in Solid Organ Transplant Recipients","volume":"24","author":"Sarrell","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72\u202f314 Cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s15010-022-01914-8","article-title":"Outcome of Lung Transplant Recipients Infected With SARS-CoV-2\/Omicron\/B.1.1.529: A Nationwide German Study","volume":"51","author":"Kneidinger","year":"2023","journal-title":"Infection"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1097\/TP.0000000000004162","article-title":"COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients during the Omicron Surge","volume":"106","author":"Cochran","year":"2022","journal-title":"Transplantation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.15585\/mmwr.mm7137a4","article-title":"Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods \u2014 United States, April 2020\u2013June 2022","volume":"71","author":"Adjei","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bjh.18782","article-title":"Systematic Review and Meta\u2010Analysis of the Clinical Effectiveness of Tixagevimab\/cilgavimab for Prophylaxis of COVID \u201019 in Immunocompromised Patients","volume":"201","author":"Suribhatla","year":"2023","journal-title":"Br J Haematol"},{"key":"B44","unstructured":"Sheet for Healthcare Providers: Emergency Use Authorization for EvusheldTM (Tixagevimab Co-Packaged with Cilgavimab)2023"},{"key":"B45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/08923973.2022.2160733","article-title":"Sotrovimab Therapy in Solid Organ Transplant Recipients with Mild to Moderate COVID-19: A Systematic Review and Meta-Analysis","volume":"45","author":"Farhadian","year":"2023","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s40472-022-00357-2","article-title":"COVID-19 and Solid Organ Transplantation: Role of Anti-SARS- CoV-2 Monoclonal Antibodies","volume":"9","author":"Dhand","year":"2022","journal-title":"Curr Transpl Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"105026","DOI":"10.1016\/j.jcv.2021.105026","article-title":"Breakthrough COVID-19 and Casirivimab-Imdevimab Treatment during a SARS-CoV-2 B1.617.2 (Delta) Surge","volume":"145","author":"Bierle","year":"2021","journal-title":"J Clin Virol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e14007","DOI":"10.1111\/tid.14007","article-title":"Outcomes of SARS-CoV-2 Infection Among Lung Transplant Recipients: A Single Center Retrospective Study","volume":"25","author":"Casutt","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B49","volume-title":"Understanding How Monoclonal Antibodies Work","author":"Malik","year":"2024"},{"key":"B50","doi-asserted-by":"publisher","first-page":"108233","DOI":"10.1016\/j.pharmthera.2022.108233","article-title":"Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human Immunoglobulin","volume":"240","author":"Otsubo","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 Variant Evasion of Monoclonal Antibodies Based on In Vitro Studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/S1473-3099(22)00663-6","article-title":"Omicron Sublineage BA.2.75.2 Exhibits Extensive Escape from Neutralising Antibodies","volume":"22","author":"Sheward","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B53","volume-title":"Latest FDA Updates for Evusheld","year":""},{"key":"B54","volume-title":"Emergency Use Authorizations for Drugs and Non-Vaccine Biological Prod","year":""},{"key":"B55","volume-title":"A Study to Evaluate the Efficacy and Safety of VYD222 for Prevention of COVID-19 (CANOPY). Identifier NCT06039449","year":"2024"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.13800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:07:28Z","timestamp":1739207248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.13800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":55,"alternative-id":["10.3389\/ti.2025.13800"],"URL":"https:\/\/doi.org\/10.3389\/ti.2025.13800","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"article-number":"13800"}}